Berry gene: The world's first third-generation gene sequencing platform SequelIICNDx approved for clinical use has obtained a medical device registration certificate.

On October 31, Berry Genomics announced that its wholly-owned subsidiary, Hangzhou Berry and Health Gene Diagnosis Technology Co., Ltd., has received a medical device registration certificate issued by the National Medical Products Administration for its third-generation gene sequencer Sequel II CNDx. The Sequel II CNDx is the world's first third-generation gene sequencing platform approved for clinical use. As of now, Berry Genomics has fully achieved the independent production of third-generation sequencing kits and the local deployment delivery of intelligent interpretation reporting systems.